Skip to main content
. 2012 Feb 1;11(3):594–603. doi: 10.4161/cc.11.3.19096

Figure 3.

Figure 3

mTorKIs inhibit 4E-BP1 phosphorylation in SW480 but not SW620 xenograft tumors. (A) Xenograft tumor mouse models were orally administered with BEZ235 at 45 mg/kg/day or PP242 at 60 mg/kg/day once daily for 28 d. Upper parts show representative tumors (as indicated by arrow-heads) in treated and control xenograft mice. Lower part shows tumor volume measurements (means ± SD; n = 8; *p < 0.01, vs. control). (B) Xenograft tumor mouse models derived from SW480 and SW620 were orally administered with BEZ235 at 45 mg/kg/day or PP242 at 60 mg/kg/day, once daily for 28 d. On day 28, CRC tumors were removed and analyzed for inhibition of PI3K-mTOR signaling by western blot. Four tumor samples from control group and 5 samples from each mTorKIs treatment group were shown here, with each lane representing an individual tumor sample.